Welcome to our dedicated page for Zentek SEC filings (Ticker: ZTEK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zentek Ltd. (ZTEK) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily furnished on Form 6-K as a foreign private issuer and linked to its Form 40-F and Form F-3 registration statement. These filings supply official documentation that complements Zentek’s press releases on technology, operations and governance.
Recent Form 6-K reports incorporate a range of exhibits, including press releases on Albany Graphite Corp.’s ultra-high purity graphite testing for nuclear and lithium-ion battery applications, the development of a Graphite Gel-Based Fire-Retardant product and related U.S. licensing agreement with Altek Advanced Materials Inc., and updates on ZenGUARD™ Enhanced Air Filters, corporate strategy and international commercialization efforts. Other 6-K filings attach unaudited condensed interim consolidated financial statements, Management’s Discussion and Analysis, and certifications of interim filings by Zentek’s senior officers.
Filings also cover corporate events such as CEO appointments, annual and special meeting voting results, omnibus long-term incentive plan approvals and responses to tax reassessment matters, all documented through exhibits to Form 6-K. For investors tracking Zentek’s advanced materials and healthcare technology activities, these filings provide the formal record of milestones first announced in news releases.
On Stock Titan, users can review these SEC submissions alongside AI-powered summaries that highlight key points from each document, helping to interpret technical content and multi-exhibit reports more efficiently. This includes quick views of technology-related disclosures, governance decisions and financial reporting contained in Zentek’s 6-Ks and other incorporated filings, updated as new documents are furnished to the EDGAR system.
Zentek Ltd. has engaged ICP Securities Inc. to provide automated market-making services using ICP’s proprietary ICP Premium® algorithm, subject to TSX Venture Exchange approval. The agreement starts April 1, 2026, runs for an initial four-month term, and renews monthly unless terminated with 30 days’ notice.
ICP will receive a monthly fee of C$7,500 plus taxes, with no performance-based compensation, stock options, or other securities-related consideration. ICP is an arm’s length party and will bear its own trading costs, aiming primarily to correct temporary supply-demand imbalances and support more orderly, liquid trading in Zentek’s shares.
Zentek Ltd. reports that its wholly owned subsidiary, Triera Biosciences, plans to launch contract research organization services focused on custom aptamer discovery, biosensor enablement, and machine-learning classification for pharma, biotech, and diagnostics clients in Canada, the United States, Europe, and other markets.
Triera’s platform is built on a 20-year exclusive, worldwide, royalty-bearing license with McMaster University covering aptamer applications developed in collaboration with the Li Lab. The business model is client-funded and asset-light, with Triera retaining underlying intellectual property and Zentek expecting these activities may help generate earlier and more predictable revenue to support its broader diagnostics and pharmaceutical initiatives.
Zentek Ltd. reports a favorable court outcome in long‑standing litigation with its former CEO and his consulting firm. The Ontario Superior Court dismissed substantially all claims, which originally exceeded $6 million, including success fee, severance, unpaid wages, defamation, and indemnification demands.
The Court denied a $282,500 success fee claim, $1,350,000 in severance claims, $51,748.82 in alleged unpaid wages, $75,000 in defamation damages, and about $194,000 in indemnification costs. Zentek’s own claim to cancel 4.5 million founder shares and recover related profits was not granted, as the shares were found to be properly issued.
The company’s CEO framed the judgment as closing a difficult chapter and emphasized focusing on core platforms Albany Graphite, ZenGUARD™ and Triera as Zentek continues to develop and commercialize graphene‑enabled and advanced material technologies.
Zentek Ltd. provided an update on its Albany Graphite Project engagement activities around the PDAC 2026 convention in Toronto. The company joined a TSX Canadian Mining Roundtable with senior federal officials to discuss Canada’s critical minerals strategy and highlighted Albany Graphite’s nuclear-grade purity and Northern Ontario location.
Zentek also met separately with federal representatives and Invest Ontario to position Albany within critical minerals funding programs. On the community side, the company participated in Indigenous consultation discussions and held a working session with Constance Lake First Nation, its Indigenous partner, to advance collaboration ahead of environmental baseline studies and a new Preliminary Economic Assessment.
The Albany Graphite deposit, held through Albany Graphite Corp., has achieved 99.9992% ultra-high purity graphite with an equivalent boron concentration of 2.60 ppm in independent bench-scale testing, meeting benchmarks for potential nuclear-grade applications and showing near-theoretical electrochemical performance for lithium-ion battery anodes.
Zentek Ltd. has begun a pilot evaluation program with U.S.-based Quality Filters Inc. to test integrating Zentek’s proprietary air filtration media into Quality’s commercial HVAC and industrial filtration product lines. The program is expected to run for about 8 to 12 weeks and will focus on product compatibility, manufacturing scalability, and performance under real-world commercial conditions.
During this period, the companies will also work on defining the commercial and technical framework for a potential long-term supply arrangement. Zentek views this as an important first step in validating its partnership-led commercialization strategy in the U.S. air filtration market, which industry research estimates could reach about US$7.3 billion by 2032. Zentek also plans to continue assessing U.S. EPA regulatory requirements in parallel with the pilot.
Zentek Ltd. is outlining how it plans to advance its Albany Graphite Project toward a new Preliminary Economic Assessment and, ultimately, a Pre-Feasibility Study. The company highlights Albany’s nuclear-grade graphite purity of 99.9992% and its fit with NATO, Canadian, and U.S. critical minerals and defence priorities.
Zentek is engaging with multiple federal and Ontario programs, including a $2‑billion Critical Minerals Sovereign Fund, tax credits, and provincial processing and innovation funds, as well as U.S. defence stockpiling initiatives. It intends to commission a new PEA, start second‑year environmental baseline studies, and continue advancing its proprietary fluidized bed reactor purification technology to systematically de-risk the project.
Zentek Ltd. outlines a sharper strategy focused on three core platforms: the Albany Graphite deposit, its ZenGUARD™ coating technology, and Triera. The company is cutting non-core activities, tightening capital allocation, and tying any future financing to evidence-based milestones to support long-term value creation.
Albany Graphite is positioned as Zentek’s lead asset, with independent tests showing it can be purified to 5N (99.9992%) graphite with boron at 2.60 ppm, suitable for nuclear applications. Over the next 12 to 18 months, Zentek aims to update its economic assessment, expand pilot-scale processing, and advance environmental and social baseline work with local communities, targeting a future spin-out, partnership or similar structure.
Zentek is also moving toward a development-on-demand model, using its coatings and ultra-high-purity carbon materials in targeted R&D programs with partners. Separately, the company continues detailed, science-based engagement with Health Canada, as ZenGUARD™ Enhanced Air Filters are currently viewed as pest control products, which could add cost and time to commercialization in Canada if that classification is finalized.
Zentek Ltd. received a further 180‑day extension from Nasdaq to regain compliance with the exchange’s minimum $1.00 bid price requirement for continued listing. The new deadline to meet Nasdaq Listing Rule 5550(a)(2) is August 24, 2026.
The company’s shares will continue to trade on Nasdaq under the symbol “ZTEK” with no immediate impact on listing or trading status. To regain compliance, Zentek must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days on or before the new deadline.
Management plans to monitor the share price and consider available options to satisfy the requirement while continuing to advance its graphene-enabled advanced material technologies across healthcare, clean air and industrial applications.
Zentek Ltd. reported a net loss of $6.24 million for the nine months ended December 31, 2025, narrowing from $8.20 million a year earlier, on modest revenue of $129,281. Cash and cash equivalents increased to $1.80 million from $121,481 as the company raised funds through equity units, an at-the-market offering, stock option exercises, and $2.0 million of 5% secured convertible debentures maturing in 2028, secured against the Albany graphite property.
Total assets were $17.38 million and shareholders’ equity $12.34 million, with an accumulated deficit of $87.70 million. Management highlights a material uncertainty about the company’s ability to continue as a going concern, given continuing losses and dependence on future financing. Zentek is pivoting toward a B2B specialty materials and IP-licensing model, advancing its ZenGUARD™ mask and HVAC filtration technologies, while receiving government grants of $471,076 and completing a gainful sale of property.
Zentek Ltd. filed a report highlighting a strategic reset described in a new shareholder letter. The company is narrowing its efforts to three core platforms: Albany Graphite, ZenGUARD, and Triera, each managed against defined milestones, capital criteria, and a 24‑month roadmap.
Zentek is pausing or winding down non-core initiatives and is reducing its cost base through workforce and facility optimization and tighter corporate spending controls. Future capital raises will be tied to specific milestones. As part of the reset, Chief Science Officer Colin van der Kuur has departed, with responsibilities redistributed across the existing technical leadership team.
The company also plans clearer segment-level financial disclosure, milestone tracking, and updated transparency standards while aligning research and development with the three core platforms.